Literature DB >> 17881666

Poor serological responses upon influenza vaccination in patients with rheumatoid arthritis treated with rituximab.

L B S Gelinck, Y K O Teng, G F Rimmelzwaan, B J F van den Bemt, F P Kroon, J M van Laar.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2007        PMID： 17881666      PMCID： PMC1994303          DOI： 10.1136/ard.2007.071878

Source DB:  PubMed          Journal:  Ann Rheum Dis        ISSN： 0003-4967            Impact factor:   19.103


× No keyword cloud information.
  7 in total

1.  Prevention and Control of Influenza: recommendations of the Advisory Committee on Immunization Practices (ACIP).

Authors:  Nicole M Smith; Joseph S Bresee; David K Shay; Timothy M Uyeki; Nancy J Cox; Raymond A Strikas
Journal:  MMWR Recomm Rep       Date:  2006-07-28

2.  Reconstitution of peripheral blood B cells after depletion with rituximab in patients with rheumatoid arthritis.

Authors:  Maria J Leandro; Geraldine Cambridge; Michael R Ehrenstein; Jonathan C W Edwards
Journal:  Arthritis Rheum       Date:  2006-02

3.  Immunization of patients with rheumatoid arthritis against influenza: a study of vaccine safety and immunogenicity.

Authors:  A Chalmers; D Scheifele; C Patterson; D Williams; J Weber; R Shuckett; A Teufel
Journal:  J Rheumatol       Date:  1994-07       Impact factor: 4.666

4.  Rituximab treatment results in impaired secondary humoral immune responsiveness.

Authors:  Lizet E van der Kolk; Joke W Baars; Martin H Prins; Marinus H J van Oers
Journal:  Blood       Date:  2002-09-15       Impact factor: 22.113

5.  Efficacy of B-cell-targeted therapy with rituximab in patients with rheumatoid arthritis.

Authors:  Jonathan C W Edwards; Leszek Szczepanski; Jacek Szechinski; Anna Filipowicz-Sosnowska; Paul Emery; David R Close; Randall M Stevens; Tim Shaw
Journal:  N Engl J Med       Date:  2004-06-17       Impact factor: 91.245

6.  Antibody response to immunization with influenza A/USSR/77 (H1N1) virus in young individuals primed or unprimed for A/New Jersey/76 (H1N1) virus.

Authors:  N Masurel; P Ophof; P de Jong
Journal:  J Hyg (Lond)       Date:  1981-10

7.  Rituximab as adjuvant to high-dose therapy and autologous hematopoietic cell transplantation for aggressive non-Hodgkin lymphoma.

Authors:  Steven M Horwitz; Robert S Negrin; Karl G Blume; Sheila Breslin; Monic J Stuart; Keith E Stockerl-Goldstein; Laura J Johnston; Ruby M Wong; Judith A Shizuru; Sandra J Horning
Journal:  Blood       Date:  2003-08-07       Impact factor: 22.113
  7 in total
  24 in total

Review 1.  Vaccination against infection in patients with multiple sclerosis.

Authors:  Micha Loebermann; Alexander Winkelmann; Hans-Peter Hartung; Hartmut Hengel; Emil C Reisinger; Uwe K Zettl
Journal:  Nat Rev Neurol       Date:  2012-01-24       Impact factor: 42.937

Review 2.  Impact of host genetic polymorphisms on vaccine induced antibody response.

Authors:  Janina E Linnik; Adrian Egli
Journal:  Hum Vaccin Immunother       Date:  2016-01-25       Impact factor: 3.452

Review 3.  A literature review on the patients with autoimmune diseases following vaccination against infections.

Authors:  Yan Liang; Fan-Ya Meng; Hai-Feng Pan; Dong-Qing Ye
Journal:  Hum Vaccin Immunother       Date:  2015       Impact factor: 3.452

4.  Impaired response to influenza vaccine associated with persistent memory B cell depletion in non-Hodgkin's lymphoma patients treated with rituximab-containing regimens.

Authors:  Davide Bedognetti; Gabriele Zoppoli; Carlotta Massucco; Elisa Zanardi; Simonetta Zupo; Andrea Bruzzone; Mario Roberto Sertoli; Enrico Balleari; Omar Racchi; Marco Messina; Graziano Caltabiano; Giancarlo Icardi; Paolo Durando; Francesco M Marincola; Francesco Boccardo; Manlio Ferrarini; Filippo Ansaldi; Andrea De Maria
Journal:  J Immunol       Date:  2011-04-15       Impact factor: 5.422

Review 5.  A comprehensive review of rituximab therapy in rheumatoid arthritis patients.

Authors:  Soheil Tavakolpour; Samira Alesaeidi; Mohammad Darvishi; Mojtaba GhasemiAdl; Sahar Darabi-Monadi; Meisam Akhlaghdoust; Somayeh Elikaei Behjati; Arash Jafarieh
Journal:  Clin Rheumatol       Date:  2019-08-01       Impact factor: 2.980

6.  [Practical problems by implementation of vaccination recommendations].

Authors:  C Fendler; E Saracbasi; F Dybowski; F Heldmann; J Braun
Journal:  Z Rheumatol       Date:  2012-02       Impact factor: 1.372

7.  Investigation of clinical characteristics as predictive factors for the humoral immune response to the influenza vaccine in patients with rheumatoid arthritis.

Authors:  Toshiaki Kogure; Naoyuki Harada; Takeshi Tatsumi; Hiroshi Fujinaga
Journal:  Clin Rheumatol       Date:  2014-01-21       Impact factor: 2.980

Review 8.  Vaccination of patients with autoimmune inflammatory rheumatic diseases.

Authors:  Johanna Westra; Christien Rondaan; Sander van Assen; Marc Bijl
Journal:  Nat Rev Rheumatol       Date:  2014-12-09       Impact factor: 20.543

9.  Vaccination response to protein and carbohydrate antigens in patients with rheumatoid arthritis after rituximab treatment.

Authors:  Maria Rehnberg; Mikael Brisslert; Sylvie Amu; Kiandoht Zendjanchi; Gunilla Håwi; Maria I Bokarewa
Journal:  Arthritis Res Ther       Date:  2010-06-08       Impact factor: 5.156

10.  [Guidelines for vaccination of immunocompromised individuals].

Authors:  Ursula Wiedermann; Harald H Sitte; Heinz Burgmann; Alexander Eser; Petra Falb; Heidemarie Holzmann; Maria Kitchen; Marcus Köller; Herwig Kollaritsch; Michael Kundi; Hans Lassmann; Ingomar Mutz; Winfried F Pickl; Elisabeth Riedl; Maria Sibilia; Florian Thalhammer; Barbara Tucek; Werner Zenz; Karl Zwiauer
Journal:  Wien Klin Wochenschr       Date:  2016-07-25       Impact factor: 1.704
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.